Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the QMM Program topic
No spam. Unsubscribe anytime.
Dr. Tuome: QMM assessments separate from enforcement; results will be anonymized
Summary
FDA panelist Dr. Tuome said the Quality Management Maturity (QMM) assessments are not currently tied to the agency's compliance program, and that published findings will anonymize company identities; FDA is discussing scaling but has no definitive rollout plan.
Dr. Tuome, a panelist on the FDA QMM discussion, told industry attendees that "currently, there is no direct relationship between the compliance program and QMM." He said the QMM effort focuses on assessing and improving firms' quality management practices, not on enforcement actions.
When asked whether firms should be concerned that assessment data would feed into compliance activity, Dr. Tuome said assessment reports are shared only within the QMM working group and provided to the assessed firm. "When we publish information... we anonymize firms, and we don't provide any firm specific data," he said. He added that FDA plans to publish cohort results for the first and second QMM cohorts, with company-identifying information removed.
On scaling the pilot, Dr. Tuome said there have been internal discussions at FDA about expanding the program but there is no definitive plan to roll the protocol out at large scale. "For the current year and the few years ahead, we will continue to use the protocol evaluation to kind of learn more about the protocol," he said, adding that FDA must ensure the protocol is robust before broader implementation.
The panel's answers were framed as procedural and informational; there was no announcement of formal policy changes or new enforcement linkages during the session.
